Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Financial Results
    • Merck Q1 net profit up...

    Merck Q1 net profit up as cancer drug, vaccine sales soar

    GarimaWritten by Garima Published On 2019-05-03T09:00:17+05:30  |  Updated On 3 May 2019 9:00 AM IST
    Merck Q1 net profit up as cancer drug, vaccine sales soar

    Gardasil, a vaccine for preventing cancers associated with human papillomavirus, powered much of the earnings beat, helped by higher vaccination rates in Europe, while other vaccines, such as the Merck's measles shot, also helped results.


    New Delhi: Merck & Co Inc reported a higher-than-expected first-quarter profit on Tuesday on increased demand for vaccines and cancer immunotherapy Keytruda, and the U.S. drugmaker raised its 2019 earnings and revenue forecasts.


    Gardasil, a vaccine for preventing cancers associated with human papillomavirus, powered much of the earnings beat, helped by higher vaccination rates in Europe, while other vaccines, such as the company's measles shot, also helped results.


    Sales of Keytruda surged 55 per cent to $2.27 billion. While shy of lofty Wall Street estimates of $2.33 billion, they topped Bristol-Myers Squibb's rival drug Opdivo, which brought in $1.8 billion, for the fourth consecutive quarter.


    Read Also: Merck wins USFDA approval for Keytruda as combo therapy for kidney cancer


    Lung cancer accounted for 65 per cent of Keytruda's U.S. sales. But it has piled up approvals to treat several other types of cancer, including a recent U.S. approval in combination with a Pfizer drug for advanced kidney cancer.


    "We are feeling very excited about the opportunities outside of the lung," Chief Commercial Officer Frank Clyburn said on a call with analysts and investors.


    The company said it now expects full-year adjusted earnings of $4.67 to $4.79 per share, up from its prior forecast of $4.57 to $4.72. It raised its 2019 revenue forecast to $43.9 billion to $45.1 billion from $43.2 billion to $44.7 billion.


    Merck shares rose 1.3 per cent to $77.80.


    Read Also: Merck Foundation defines interventions to break infertility stigma at IFFS World Congress


    Gardasil sales rose 27 per cent to $828 million, beating analyst expectations by about $25 million.


    Sales of the company's measles-mumps-rubella and chickenpox vaccines rose 27 per cent to $496 million, helped by government tenders in Latin America and higher European and U.S. demand.


    Measles cases in the United States have hit their highest level since the virus was declared eradicated in 2000, with a total of at least 705 confirmed cases so far. Merck is the sole provider of the measles-mumps-rubella vaccine.


    The company said it plans a restructuring program to optimize its manufacturing and supply network and cut its real estate footprint, and expects to take related charges of $500 million in 2019.


    Excluding items, Merck earned $1.22 per share, beating the analysts' average estimate by 16 cents, according to IBES data from Refinitiv.


    Read Also: Astrazeneca, Merck wins EU nod for Lynparza to treat breast cancer


    Net income nearly quadrupled to $2.92 billion from $736 million a year earlier, when the company had taken a $1.4 billion charge related to a collaboration deal with Japanese drugmaker Eisai Co Ltd.


    Sales rose to $10.81 billion, topping Wall Street estimates of $10.48 billion.

    Bristol-Myers Squibbcancercancer immunotherapycancer immunotherapy Keytrudachickenpoxchickenpox vaccinesdrug OpdivoEisai Co LtdFrank ClyburnGardasilKeytrudalung cancermeaslesMerckMerck & CoMerck sharesmumpspapillomavirusPfizer drugrubellaUnited Statesvaccines
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Garima
    Garima

      Garima joined Medical Dialogues in the year 2017 and is currently working as a Senior Editor. She looks after all the Healthcare news pertaining to Medico-legal cases, MCI/DCI decisions, Medical Education issues, government policies as well as all the news and updates concerning Medical and Dental Colleges in India. She is a graduate from Delhi University. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok